A polysaccharide from the dried rhizome of Drynaria fortunei (Kunze) J. Sm. prevents ovariectomized (OVX)‐induced osteoporosis in rats

Sun, Xin; Wei, Bo; Peng, Zheng; Chen, Xiaru; Fu, Qinglong; Wang, Chaojun; Zhen, Jinchang; Sun, Jiecong

doi:10.1111/jcmm.15072

Cited by 16 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In modern pharmacological studies of traditional oriental medicines, the polysaccharides of herbal medicines have been confirmed as major bioactive components, which are responsible for various pharmacological activities such as antioxidant, antitumor, anti-hyperglycemic and immune-stimulatory activities [ 32 ]. Especially, several recent studies have demonstrated that bioactive polysaccharides isolated from different plants have potent anti-osteoporotic effects in vivo [ 33 , 34 , 35 ]. In our study, C. myrrha resin-derived polysaccharides (i.e., WCM-PE) markedly inhibited RANKL-induced osteoclastogenesis, which was similar to that of WCM.…”

Section: Discussionmentioning

confidence: 99%

Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition

Hwang

Lee

Kim

et al. 2021

Plants

View full text Add to dashboard Cite

In traditional oriental medicines, Commiphora myrrha and its resinous exudate (i.e., myrrh) are used as herbal remedies to treat various inflammatory and metabolic disorders. Until now, C. myrrha-derived herbal products are considered useful source for bioactive compounds to manage numerous human diseases. This study investigated the effects of water extract of C. myrrha resin (WCM) and its polysaccharide (WCM-PE) on modulatory effects of osteoclast differentiation and/or ovariectomized-induced bone loss. Oral administration of WCM (200 and 500 mg/kg/day for four weeks) notably decreased trabecular bone loss and lipid accumulation in the bone marrow cavity. WCM and WCM-PE dose-dependently inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and suppressed RANKL-mediated overexpression of c-Fos and nuclear factor of activated T cells, cytoplasmic 1, thereby downregulating osteoclast-specific gene (Atp6v0d2, DC-STAMP and cathepsin K) expression. Thus, our results suggest that WCM and WCM-PE are promising nutraceutical candidates for the management of osteoporosis in postmenopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition

Hwang

Lee

Kim

et al. 2021

Plants

View full text Add to dashboard Cite

show abstract

“…Eucommiae Cortex , rich in polyphenols such as phenolic acids, flavonoids, and lignans, is a kidney-tonifying herbal medicine that has been shown to improve bone histomorphometric parameters in lead-exposed rats. The possible mechanism underlying the effects of Eucommia Cortex extract is the promotion of bone formation by increasing the expression of OPG and the suppression of bone resorption by decreasing the level of RANKL in serum [ 22 ]. Gentiopicroside is the main active ingredient of Gentiana macrophylla Pall., which significantly suppresses RANKL-induced osteoclast formation in bone marrow mesenchymal stem cells (BMMs), with the possible mechanism being the inhibition of RANKL-induced activation of NF- κ B and Jun N-terminal kinase (JNK) signaling pathways in BMMs [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

“…[ 21 ] increases bone mineral density (BMD) content by improving the level of OPG and reducing the level of RANKL in ovariectomy-induced mice. Drynariae Rhizoma enhances the strength and hardness of bone [ 22 ]. Meanwhile, our previous studies reported that Drynaria flavonoids improve osteoporosis by promoting the expression of OPG and inhibiting RANKL and RANK in the sera of osteoporosis model rats [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis

Cui

Wen-hua

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

QiangGuYin (QGY) is a common Traditional Chinese medicine prescription for the treatment of osteoporosis. Previous clinical studies have found that QGY effectively improves bone mineral density (BMD) in postmenopausal women, but its underlying mechanism remains unclear. The osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa B (RANK) pathway is a classic pathway involved in osteoporosis. Secretin levels are a serum marker of osteoporosis, but their effect on the OPG/RANKL/RANK pathway has not been reported. Hence, we investigated the relationship between the OPG/RANKL/RANK pathway and secretin and further revealed the mechanism underlying the effect of QGY in the treatment of osteoporosis. Mice were divided into secretin knockdown, secretin overexpression, and corresponding control groups. Micro-computed tomography was used to detect BMD in different groups, and the results show that QGY significantly improved BMD in mice of the secretin knockdown group. To further verify this, the serum levels of OPG, RANKL, RANK, and secretin were measured by enzyme-linked immunosorbent assays, and femur levels of OPG, RANKL, RANK, and secretin were evaluated by real-time quantitative PCR and western blotting. The results show that the expression of OPG was inhibited and that of RANKL and RANK was increased in mice from the secretin knockdown group, whereas the expression of OPG was upregulated and that of RANKL and RANK was downregulated after QGY intervention. Therefore, QGY inhibited bone resorption by promoting the expression of secretin and modulating the OPG/RANKL/RANK pathway. In addition to the effect of QGY, we also revealed the general regulatory effect of secretin on the OPG/RANKL/RANK pathway. We conclude that QGY modulates the OPG/RANKL/RANK pathway by increasing secretin levels during treatment of primary type I osteoporosis. This work provides a theoretical basis for the clinical use of QGY in the treatment of osteoporosis.

show abstract

“…Sun et al reported that polysaccharides from Rhizoma Drynariae exerts an antiosteoporotic effect in ovariectomized rats. It maintained trabecular microarchitecture and bone biomechanical properties, and increased femoral and tibial bone mineral density (BMD) [ 144 ].…”

Section: Other Botanicalsmentioning

confidence: 99%

Botanicals in Postmenopausal Osteoporosis

2021

View full text Add to dashboard Cite

Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures. Conventional anti-osteoporotic pharmaceutics are effective in the treatment and prophylaxis of osteoporosis, however they are associated with various side effects that push many women into seeking botanicals as an alternative therapy. Traditional folk medicine is a rich source of bioactive compounds waiting for discovery and investigation that might be used in those patients, and therefore botanicals have recently received increasing attention. The aim of this review of literature is to present the comprehensive information about plant-derived compounds that might be used to maintain bone health in perimenopausal and postmenopausal females.

show abstract

A polysaccharide from the dried rhizome of Drynaria fortunei (Kunze) J. Sm. prevents ovariectomized (OVX)‐induced osteoporosis in rats

Cited by 16 publications

References 52 publications

Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition

Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition

QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis

Botanicals in Postmenopausal Osteoporosis

Contact Info

Product

Resources

About